Qelbree

Chemical Nameviloxazine
Dosage FormExtended-release capsule (oral; 100 mg, 150 mg, 200 mg)
Drug ClassSelective norepinephrine reuptake inhibitors
SystemNervous
CompanySupernus Pharmaceuticals
Approval Year2021

Indication

  • For the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older.
Document TitleYearSource
Qelbree (viloxazine) Prescribing Information.2022Supernus Pharmaceuticals, Inc. Rockville, MD
Drug updated on 12/7/2022

More on this drug: Clinical Trials